Overweight and Obesity as Prognostic Factors for Survival in Children With Acute Lymphoblastic Leukemia
NCT04271215 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200
Last updated 2022-07-20
Summary
Background: Mexico City has one of the highest incidences and mortality rates of acute lymphoblastic leukemia (ALL) in the world and a high frequency of early relapses (17%) and early mortality (15%). Otherwise, childhood overweight and obesity are reaching epidemic proportions. They have been associated with poor outcomes in children with ALL. The aim of present study is to identify if overweight and obesity are prognostic factors associated with survival rates in Mexican children with ALL. Methods: Multicenter cohort study. ALL children younger than 15 years old are included and followed-up. Overweight and obesity are classified according World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) criteria. Deaths and relapses are the main outcomes.
Conditions
- Leukemia, Lymphoblastic
Interventions
- OTHER
-
Chemotherapy protocol used
Chemotherapy protocol used in each participating hospital
Sponsors & Collaborators
-
Coordinación de Investigación en Salud, Mexico
lead OTHER_GOV
Principal Investigators
-
Juan M Mejía-Arangure, PhD · Instituto Mexicano del Seguro Social/Instituto Nacional de Medicina Genomica
Eligibility
- Min Age
- 1 Day
- Max Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-01-01
- Primary Completion
- 2021-12-31
- Completion
- 2022-12-31
Countries
- Mexico
Study Locations
More Related Trials
-
Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients
NCT01999413 ·Status: COMPLETED ·Phase: PHASE2
-
Results From a Mexican Acute Promyelocytic Leukemia.
NCT04562818 ·Status: COMPLETED
-
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
NCT05137860 ·Status: UNKNOWN ·Phase: PHASE4
-
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
NCT00900445 ·Status: WITHDRAWN
-
Quality of Life Study for Adult Patients With Acute Lymphoblastic Leukemia
NCT01148927 ·Status: COMPLETED
-
Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study.
NCT04311060 ·Status: NOT_YET_RECRUITING
-
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290 ·Status: COMPLETED
-
Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors
NCT00664131 ·Status: COMPLETED
-
A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers
NCT05541224 ·Status: COMPLETED
-
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01246622 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Acute Myeloblastic Leukemia in Younger Patients
NCT00390715 ·Status: COMPLETED
-
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
NCT00801346 ·Status: COMPLETED
-
Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia
NCT03118128 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT03647124 ·Status: COMPLETED
-
AC220 for Children With Relapsed/Refractory ALL or AML
NCT01411267 ·Status: COMPLETED ·Phase: PHASE1
-
RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML
NCT01307241 ·Status: UNKNOWN
-
First Report, Five Years Experience of the Acute Leukemia Work Group
NCT02990104 ·Status: UNKNOWN
-
Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia
NCT06918054 ·Status: RECRUITING ·Phase: PHASE4
-
Clinical Characteristics of Patients With Leukemia and COVID-19
NCT04745416 ·Status: COMPLETED
-
Study of Palbociclib in MLL-rearranged Acute Leukemias
NCT02310243 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia
NCT01438138 ·Status: COMPLETED
-
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
NCT00412243 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia
NCT01279096 ·Status: COMPLETED ·Phase: PHASE1
-
Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
NCT01380587 ·Status: COMPLETED